At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 1,353 enrolled
Drug / intervention
Bimekizumabdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Open-Label Study to Assess the Long-Term Safety, Tolerability, and Efficacy of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis
In Brief
A Phase 3 clinical trial evaluating Bimekizumab for Chronic Plaque Psoriasis and Moderate to Severe Chronic Plaque Psoriasis. Completed, enrolled 1,353 participants across 189 sites in 13 countries.
Detailed Summary
This is a study to evaluate the long-term safety and tolerability of bimekizumab in adult subjects with moderate to severe chronic plaque psoriasis (PSO).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesAustralia, Belgium, Canada, Germany, Hungary, Italy, Japan, Poland, Russia, South Korea, Taiwan, United Kingdom, United States
Collaborators--
Timeline
Phase 3CompletedFinished
20192020202120222023202420252026
First PostedJul 2018
Enrollment StartSep 2018
Primary CompletionNov 2023
TodayJul 2026
First PostedJul 26, 2018
Enrollment StartSep 5, 2018
Primary CompletionNov 14, 2023
TodayJul 2, 2026
Enrollment to primary: 5.2 yearsPosted 7.9 years ago
Interventions
Bimekizumabdrug
Subjects will receive bimekizumab at pre-specified time-points.